DRUG-INDUCED ENCEPHALOPATHY WITH IMPAIRED COGNITIVE FUNCTIONS DURING TOCILIZUMAB USE

DRUG-INDUCED ENCEPHALOPATHY WITH IMPAIRED COGNITIVE FUNCTIONS DURING TOCILIZUMAB USE

Blockade of interleukin-6 (IL-6) is one of the most promising areas in the treatment of a number of immunoinflammatory diseases. Tocilizumab (TCZ), the first registered anti-IL-6 receptor monoclonal antibody, has been used effectively by rheumatologists since 2010. During this period, the spectrum o...

Full description

Bibliographic Details
Main Authors: P. A. Shesternya, S. V. Prokopenko, E. Yu. Mozheiko, O. D. Gritsenko, T. V. Tupaeva, E. M. Kurts
Format: Article
Language:Russian
Published: IMA-PRESS LLC 2019-09-01
Series:Научно-практическая ревматология
Subjects:
tocilizumab
rheumatoid arthritis
interleukin-6
adverse reaction
cognitive dysfunction
tofacitinib
Online Access:https://rsp.mediar-press.net/rsp/article/view/2764
id doaj-7ebdd2636886474eaf71713fdcc6ddaf
record_format Article
spelling doaj-7ebdd2636886474eaf71713fdcc6ddaf2021-08-02T09:05:53ZrusIMA-PRESS LLCНаучно-практическая ревматология1995-44841995-44922019-09-0157448248510.14412/1995-4484-2019-482-4852523DRUG-INDUCED ENCEPHALOPATHY WITH IMPAIRED COGNITIVE FUNCTIONS DURING TOCILIZUMAB USEP. A. Shesternya0S. V. Prokopenko1E. Yu. Mozheiko2O. D. Gritsenko3T. V. Tupaeva4E. M. Kurts5Prof. V.F. Voino-Yasenetsky Krasnoyarsk State Medical UniversityProf. V.F. Voino-Yasenetsky Krasnoyarsk State Medical UniversityProf. V.F. Voino-Yasenetsky Krasnoyarsk State Medical UniversityProf. V.F. Voino-Yasenetsky Krasnoyarsk State Medical UniversityProf. V.F. Voino-Yasenetsky Krasnoyarsk State Medical UniversityProf. V.F. Voino-Yasenetsky Krasnoyarsk State Medical UniversityBlockade of interleukin-6 (IL-6) is one of the most promising areas in the treatment of a number of immunoinflammatory diseases. Tocilizumab (TCZ), the first registered anti-IL-6 receptor monoclonal antibody, has been used effectively by rheumatologists since 2010. During this period, the spectrum of adverse reactions (ARs) of TCZ has been clearly defined. However, the multifaceted biological effects of IL-6 determine the probability of unexpected ARs. The article describes a clinical case of drug-induced encephalopathy with cognitive dysfunction during TCZ therapy.https://rsp.mediar-press.net/rsp/article/view/2764tocilizumabrheumatoid arthritisinterleukin-6adverse reactioncognitive dysfunctiontofacitinib
collection DOAJ
language Russian
format Article
sources DOAJ
author P. A. Shesternya
S. V. Prokopenko
E. Yu. Mozheiko
O. D. Gritsenko
T. V. Tupaeva
E. M. Kurts
spellingShingle P. A. Shesternya
S. V. Prokopenko
E. Yu. Mozheiko
O. D. Gritsenko
T. V. Tupaeva
E. M. Kurts
DRUG-INDUCED ENCEPHALOPATHY WITH IMPAIRED COGNITIVE FUNCTIONS DURING TOCILIZUMAB USE
Научно-практическая ревматология
tocilizumab
rheumatoid arthritis
interleukin-6
adverse reaction
cognitive dysfunction
tofacitinib
author_facet P. A. Shesternya
S. V. Prokopenko
E. Yu. Mozheiko
O. D. Gritsenko
T. V. Tupaeva
E. M. Kurts
author_sort P. A. Shesternya
title DRUG-INDUCED ENCEPHALOPATHY WITH IMPAIRED COGNITIVE FUNCTIONS DURING TOCILIZUMAB USE
title_short DRUG-INDUCED ENCEPHALOPATHY WITH IMPAIRED COGNITIVE FUNCTIONS DURING TOCILIZUMAB USE
title_full DRUG-INDUCED ENCEPHALOPATHY WITH IMPAIRED COGNITIVE FUNCTIONS DURING TOCILIZUMAB USE
title_fullStr DRUG-INDUCED ENCEPHALOPATHY WITH IMPAIRED COGNITIVE FUNCTIONS DURING TOCILIZUMAB USE
title_full_unstemmed DRUG-INDUCED ENCEPHALOPATHY WITH IMPAIRED COGNITIVE FUNCTIONS DURING TOCILIZUMAB USE
title_sort drug-induced encephalopathy with impaired cognitive functions during tocilizumab use
publisher IMA-PRESS LLC
series Научно-практическая ревматология
issn 1995-4484
1995-4492
publishDate 2019-09-01
description Blockade of interleukin-6 (IL-6) is one of the most promising areas in the treatment of a number of immunoinflammatory diseases. Tocilizumab (TCZ), the first registered anti-IL-6 receptor monoclonal antibody, has been used effectively by rheumatologists since 2010. During this period, the spectrum of adverse reactions (ARs) of TCZ has been clearly defined. However, the multifaceted biological effects of IL-6 determine the probability of unexpected ARs. The article describes a clinical case of drug-induced encephalopathy with cognitive dysfunction during TCZ therapy.
topic tocilizumab
rheumatoid arthritis
interleukin-6
adverse reaction
cognitive dysfunction
tofacitinib
url https://rsp.mediar-press.net/rsp/article/view/2764
work_keys_str_mv AT pashesternya druginducedencephalopathywithimpairedcognitivefunctionsduringtocilizumabuse
AT svprokopenko druginducedencephalopathywithimpairedcognitivefunctionsduringtocilizumabuse
AT eyumozheiko druginducedencephalopathywithimpairedcognitivefunctionsduringtocilizumabuse
AT odgritsenko druginducedencephalopathywithimpairedcognitivefunctionsduringtocilizumabuse
AT tvtupaeva druginducedencephalopathywithimpairedcognitivefunctionsduringtocilizumabuse
AT emkurts druginducedencephalopathywithimpairedcognitivefunctionsduringtocilizumabuse
_version_ 1721235645685301248

Similar Items